Grey Wolf Therapeutics completes £2.5 million Series A2 financing to accelerate development of therapies targeting ERAP2
Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for immuno-oncology (IO), announces it has completed...